SPECIAL NOTICE
Q -- Prospective Evaluation of Immunologic and IMMunogenetic susceptibility to Mycobacterium tuberculosis infection and progression to disease
- Notice Date
- 4/2/2007
- Notice Type
- Special Notice
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, Center for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, GA, 30341-4146, UNITED STATES
- ZIP Code
- 00000
- Solicitation Number
- 2007-Q-09468
- Response Due
- 4/11/2007
- Archive Date
- 4/20/2007
- Description
- Title: Prospective Evaluation of Immunologic and Immunogenetic Susceptibility to Mycobacterium Tuberculosis infection and progression to disease The Centers for Disease Control and Prevention, National Center for HIV, Hepatitis, STD, and Tuberculosis Prevention intends to award a sole source contract under Simplified Acquisition procedures to Laboratories at Bonfils, Inc., 717 Yosemite Street, Denver, Colorado 80230-6918, the only source that has access to prior data required to perform this contract. In 2002, CDC funded Laboratories At Bonfils to perform the HLA testing required for this project. Developing HLA typing assays and performing HLA testing is a specialized skill. The sensitivity and specificity of HLA assays for the same parameter vary from laboratory to laboratory. To maintain comparability of results, it is important that all samples be tested in a single laboratory. It is essential to the scientific quality of the results that the remainder of the HLA assays for the study also be performed in the same laboratory. Fifteen thousand of the 1,986 samples have been tested and collected for this project. CDC is now preparing the final 486 samples for HLA typing. The vendor will perform HLA Class II typing for DRB1 and DQB1 for 486 DNA samples through specimen number 1986. DNA will be extracted from whole blood samples. DNA samples will be shipped to the vendor for HLA testing. HLA Class II typing for DRB and DRQ alleles will be performed using Luminex DNA micro-particle bead technology. Results will be decoded by the vendor before submission to CDC. Results of this work serve as a critical step in the process of developing and testing new candidate vaccines for tuberculosis. The period of performance is 4 months from date of award. This is not a request for competitive proposals and no solicitation is available. A determination by the Government not to compete this proposed action based on response to this notice is solely with the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Contractors must be registered in the Central Contractor Registration (CCR). Contractors may register by calling 1-888-227-2423 or register via the Internet at www.ccr.gov. Registration Notification of any changes shall be made only through FedBizOpps, http://ww.fedbizopps.gov. Capability statements may be faxed to (404) 639-8095, ATTN: Ms. Johnson or emailed to chj5@cdc.gov. The date specified for receipt is April 11, 2007, 9:00 a.m. EST.
- Place of Performance
- Address: Department of Health and Human Services, Center for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine road, Room 3000, Atlanta, GA
- Zip Code: 30341-4146
- Country: UNITED STATES
- Zip Code: 30341-4146
- Record
- SN01264183-W 20070404/070402220241 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |